sorafenib has been researched along with alprostadil in 2 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (alprostadil) | Trials (alprostadil) | Recent Studies (post-2010) (alprostadil) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 7,136 | 864 | 761 |
Protein | Taxonomy | sorafenib (IC50) | alprostadil (IC50) |
---|---|---|---|
Multidrug resistance-associated protein 4 | Homo sapiens (human) | 2.3 | |
Solute carrier organic anion transporter family member 2B1 | Rattus norvegicus (Norway rat) | 0.0358 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hussar, DA | 1 |
Bito, T; Hirai, M; Hirano, T; Ishida, T; Nakagawa, T; Nishigori, C; Shichiri, H; Tokura, M; Uda, A; Yamamoto, K; Yano, I | 1 |
2 other study(ies) available for sorafenib and alprostadil
Article | Year |
---|---|
New drugs 07, part I.
Topics: Abatacept; Acetanilides; Alprostadil; Anidulafungin; Antidiuretic Hormone Receptor Antagonists; Antifungal Agents; Antineoplastic Agents; Arabinonucleosides; Benzazepines; Benzenesulfonates; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Echinocandins; Fatty Acids; Humans; Hypoglycemic Agents; Immunoconjugates; Immunosuppressive Agents; Indoles; Insulin; Insulin Detemir; Insulin, Long-Acting; Intercellular Signaling Peptides and Proteins; Lenalidomide; Lubiprostone; Niacinamide; Patient Education as Topic; Peptides, Cyclic; Phenylurea Compounds; Piperazines; Pyridines; Pyrroles; Ranolazine; Sorafenib; Sunitinib; Thalidomide; United States | 2007 |
Prostaglandin E
Topics: Alprostadil; Antineoplastic Agents; Cell Line; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; Hand-Foot Syndrome; Humans; Keratinocytes; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Skin; Sorafenib; STAT3 Transcription Factor | 2017 |